Search

everythinglearnresearchcommunity

for

Search:↓

Non-biologic immunosuppressive drugs are crucial for treating autoimmune and chronic inflammatory skin diseases.

Psoriasis patients are willing to pay less than the cost of biologic treatments for remission and don't expect complete or long-term symptom clearance.

Hormonal therapy changes skin and hair in transgender patients, who need better researched dermatologic care.

The combined therapy significantly increased hair density and was safe for treating hair loss.

PRP therapy is a promising and well-tolerated treatment for hair loss.

Stem cell therapy shows promise in improving burn wound healing.

Stem cells could potentially rebuild missing structures in wounds, improving facial skin replacement techniques.

Stem-cell therapy shows promise for skin conditions but needs more research.

The document concludes that systemic therapy is becoming more important in treating head and neck cancer, with new treatments showing promise.

Updated treatments for female hair loss include minoxidil, antiandrogens, hair transplants, and light therapy.

Injectable platelet-rich fibrin is a safe and effective treatment for hair loss.

HS patients rarely see dermatologists, often get opiates, and need better care.

Nanotechnology is improving drug delivery and targeting, with promising applications in cancer treatment, gene therapy, and cosmetics, but challenges remain in ensuring precise delivery and safety.

Get head MRI for babies with achondroplasia early, use free immunoglobulin light chains to detect certain neurodevelopmental disorders, and video calls work for speech therapy in patients with facial anomalies.

The document summarizes important skin care topics for non-specialist doctors, including treatments for skin conditions and the management of skin diseases.

The document concludes that treatment for cutaneous T-cell lymphoma should be customized to each patient's disease stage, balancing benefits and side effects, with no cure but many patients living long lives.

The document concludes that there is a significant lack of reporting on the sex and age of cells in skin research, which could affect clinical trials and treatments.

New treatments for skin conditions in children include a preferred drug for birthmark reduction, proactive creams for eczema and vitiligo, a safe psoriasis medication, and special tissues and socks for eczema and fungal infections.

This special edition focuses on the unique aspects of treating skin conditions in women, including during pregnancy and in diverse populations like women of color and transgender patients.

The document summarizes recent dermatological treatments and advances in areas like pediatric care, wound healing, skin closure, light-based therapies, pigment disorders, hair loss, immunotherapy, infection management, melanoma, drug reactions, and facial rejuvenation.

The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.

Visible light can damage skin and most sunscreens don't block it well; more research is needed on its effects and protection methods.

Some women with acne have higher levels of free testosterone, which might suggest using hormonal treatments for acne.

Systemic glucocorticosteroids are a primary treatment for various skin conditions but require careful management due to potential side effects and relapses.

The document explains hair biology, the causes of hair loss, and reviews various hair loss treatments.

Some drugs, especially biologics, can cause skin reactions that look like other skin diseases, and stopping the drug usually helps clear up these reactions.

Non-surgical treatments like thread lifts, PRP therapy, HIFU, and radiofrequency effectively rejuvenate and tighten facial skin.

The document concludes that individualized treatment and lifestyle changes are important for managing menopause symptoms and health risks.

TNF-alpha inhibitors can cause various immune-related skin issues.

Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.